The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.
Adzenys, as the chewable, fruity medication is called, packs the punch of Adderall and is geared toward children with attention deficit hyperactivity disorder.
The drug hit the market last week and is already stirring controversy: Some psychiatrists worry that Adzenys will accelerate a trend toward overmedicating kids — and could be yet another gateway into ADHD drug abuse.
Adzenys, an extended-release amphetamine, was approved by the Food and Drug Administration in January for patients 6 years and older. It comes in six dose strengths. The Dallas company behind the drug, Neos Therapeutics, began ramping up commercial efforts in order to get “ahead of back-to-school season,” CEO Vipin Garg said.
There’s a very real population of children and adults whose lives are vastly improved by medications like Adderall and Ritalin, which stimulate the central nervous system and affect chemicals in the brain associated with impulse control. But the line between need and want is increasingly blurry.
About 75 percent of children diagnosed with ADHD are on medication — a statistic that concerns many psychiatrists.
Read full, original post: Tasty and easy to take, new ADHD drug alarms some psychiatrists